| Theme |
Intestinal Behçet's disease and simple ulcer of the intestine |
| Title |
Treatment for intestinal Behçet's disease -- Review of The 2nd edition of consensus statements for diagnosis and management of intestinal Behçet's disease |
| Author |
Tadakazu Hisamatsu |
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine |
| Author |
Fumiaki Ueno |
Center for Digestive and Liver Diseases, Ohfuna Chuo Hospital |
| Author |
Toshifumi Hibi |
Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital |
| [ Summary ] |
Little clinical evidence is available regarding the management of patients with intestinal Behçet's disease (BD), despite recognition that the presence of intestinal lesions is a negative prognostic factor. These cause perforations and massive bleeding and are associated with a negative impact on patients' QOL. In 2007, the 1st edition of the consensus statements for diagnosis and management of intestinal BD was published in Japan. Many recent case reports have suggested that infliximab, anti-TNFα monoclonal antibody (mAb), is effective for treating patients with intestinal BD. In addition, in 2013, adalimumab was approved in Japan for the treatment of intestinal BD. Because of changes in clinical settings, the 2nd edition of the consensus statements was developed in 2013. The 2nd edition of those consensus statements for diagnosis and management of intestinal BD and discussions concerning problems confronting us are reviewed. |